Aktienanalyse zu KORU Medical Systems Inc (KRMD)KRMDKORU Medical Systems Inc

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

KORU Medical Systems Inc is currently priced at $3.23, which is significantly below the analyst price targets of $6 and $8, indicating potential upside. However, the stock has a low RSI of 31.63, suggesting it is oversold, but the forward P/E ratio of 188.68 indicates high valuation concerns. The company has shown revenue growth with Q2 2026 revenue at $12.05 million, but it has also reported a net income loss of $807,078 in Q1 2026. The main risk is the high forward P/E ratio, which could indicate overvaluation if growth does not materialize as expected.